Pharma & Bio
Technology
Vaxcell, the Biggest Beneficiary of Regenerative Medicine Reform [K-Bio Pulse]
On the 29th, South Korea’s pharmaceutical and life sciences sectors posted strong gains. The pharmaceutical index rose 9.52%, with 143 of 160 listed companies advancing, while the life sciences index …
Venture
Lee Soo-jae, CEO of FNCT Biotech: "CSF3 Antibody Restores Stiffened Lungs to Their Original State... Discussing Technology Transfer with Big Pharma"
FNCT Biotech, a developer of new drugs for fibrosis and cancer treatment, has successfully completed its Series B funding round, raising its pre-IPO valuation to the 600억 won range. FNCT Biotech has i…
Technology
'The Warring States Period of Insulin Pumps'… CareMedi, EOFlow Co., Ltd., and CureStream Clash
The domestic patch-type insulin pump market is entering a competitive phase. CareMedi’s CareRevo—the second domestically produced insulin pump to receive approval in five years—was recently launched, …
Lifestyle
"Obesity Drugs That Cause Muscle Loss Have Their Limits"... DaewonPharmaceutical Bets on 'Quadruple-Action Agent' Beyond GLP-1
The obesity treatment market is rapidly evolving beyond simple weight loss, with competition now centered on innovations in dosage forms, administration schedules, and mechanisms of action. As the mar…
Lifestyle
Cellid Crashes in After-Hours Trading Following Phase 3 Failure...Shaperon Plummets 25% [K-bio pulse]
In the biopharmaceutical sector on Friday, Cellid’s stock surged on expectations for its vaccine clinical trial results, but the shares plunged by the daily limit in after-hours trading following news…
Lifestyle
Cellid Co., Ltd. Hits After-Hours Lower Circuit Breaker Following Phase 3 ‘Failure’… Shaperon Inc. Also Drops 25% [Bio Spotlight]
On the 26th, shares of Cellid Co., Ltd.(299660) surged significantly in the pharmaceutical and biotech sector amid expectations for the announcement of clinical trial results for a vaccine currently i…
Lifestyle
'U.S. Government Streamlines Clinical Trial Plans and Phase 1 Procedures'... Celltrion Gains Momentum for 20 New Drugs
Celltrion(068270)is expected to further accelerate its global new drug development efforts, buoyed by the U.S. health authorities’ sudden policy shift toward clinical development innovation. At a time…
Lifestyle
Embolization Techniques: Shift from Permanent to Temporary Occlusion... NextBio’s Value Set to Rise
The paradigm in the embolization (a procedure that treats lesions by blocking blood vessels) market is shifting. The medical community appears to be shifting away from the traditional approach of perm…
Technology
'From FDA Approval to Phase 3 Topline Results'… What Are the Major K-Bio Events to Watch in the Second Half of the Year?
As capital flowed into semiconductor and artificial intelligence (AI) companies, domestic pharmaceutical and biotech firms were relatively sidelined in the first half of this year. Although quite a fe…
Lifestyle
[BioUSA] Fred Kim, U.S. Branch Manager of AriBio: “Fushing Pharmaceutical Is Also Interested in Other Pipeline Projects... Potential for Further Collaboration”
At the BioUSA event held in San Diego, USA, until just last year, #AriBio had to actively seek out global pharmaceutical companies and investors to introduce the company and request meetings. However,…